List of Excipients in Branded Drug HYSINGLA ER

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Knoa Pharma LLC	HYSINGLA ER	hydrocodone bitartrate	59011-272	BUTYLATED HYDROXYTOLUENE
Knoa Pharma LLC	HYSINGLA ER	hydrocodone bitartrate	59011-272	CELLULOSE, MICROCRYSTALLINE
Knoa Pharma LLC	HYSINGLA ER	hydrocodone bitartrate	59011-272	FERRIC OXIDE YELLOW
Knoa Pharma LLC	HYSINGLA ER	hydrocodone bitartrate	59011-272	HYDROXYPROPYL CELLULOSE
Knoa Pharma LLC	HYSINGLA ER	hydrocodone bitartrate	59011-272	MAGNESIUM STEARATE

Hysingla ER Excipient Strategy and Commercial Opportunities

Last updated: August 17, 2026

Hysingla ER is an extended-release hydrocodone bitartrate tablet that uses a high-viscosity polymer matrix, hydrophobic release control, and tablet mechanical strength to support 24-hour dosing and abuse-deterrent properties. Its excipient opportunity is concentrated in functional polymers, controlled-release processing, abuse-deterrent platform technology, and generic development rather than in commodity ingredients alone.

What is Hysingla ER and how does its formulation work?

Hysingla ER contains hydrocodone bitartrate, a Schedule II opioid agonist, in once-daily extended-release tablets available in strengths from 20 mg through 120 mg.[1]

The formulation is designed to:

• Release hydrocodone over approximately 24 hours.
• Maintain dose proportionality across multiple strengths.
• Resist crushing and mechanical manipulation.
• Reduce the ability to rapidly extract hydrocodone from the dosage form.
• Provide a commercially manufacturable tablet with sufficient hardness and controlled dissolution.

The FDA approved Hysingla ER in 2014. The product carries labeling describing abuse-deterrent properties based on physical and chemical manipulation studies. The FDA does not represent the formulation as abuse-proof, and the labeling states that abuse-deterrent technology does not eliminate the risks of misuse, addiction, overdose, or diversion.[1]

What excipients are used in Hysingla ER?

The FDA product labeling identifies the following inactive ingredients:

Excipient	Likely formulation role
Hypromellose	Hydrophilic matrix former and viscosity-building release-control polymer
Ethylcellulose	Hydrophobic release modifier and barrier-forming polymer
Lactose monohydrate	Diluent and tablet mass-balancing agent
Povidone	Binder and processing aid
Colloidal silicon dioxide	Glidant and flow-enhancement agent
Magnesium stearate	Lubricant

Hysingla ER is film-coated. The coating supports identification, swallowability, handling, and product differentiation, but the principal release-control and abuse-deterrent functions reside in the tablet core.[1]

Why are hypromellose and ethylcellulose commercially important?

The central excipient strategy combines hydrophilic and hydrophobic release-control mechanisms.

Hypromellose hydrates after contact with gastrointestinal fluid and forms a viscous gel layer. The gel slows penetration of fluid into the tablet and restricts diffusion of dissolved hydrocodone. Polymer viscosity grade, particle size, substitution type, compression force, and polymer concentration can materially change the dissolution profile.

Ethylcellulose contributes a less water-permeable phase. It can reduce rapid liquid penetration and limit the amount of drug that becomes immediately available after crushing or solvent exposure. The combination allows the formulator to tune release kinetics beyond what a single polymer system would provide.

This polymer pairing creates several commercial opportunities:

1. Development of high-viscosity hypromellose grades for opioid and non-opioid extended-release products.
2. Supply of functionalized ethylcellulose grades with consistent particle-size distribution.
3. Co-processed polymer systems that improve direct compression.
4. Excipient platforms that maintain dissolution performance after tablet crushing.
5. Process analytical technology for polymer distribution and tablet density.

The most defensible commercial position is not ownership of hypromellose or ethylcellulose as chemical entities. Those materials are widely available. The value lies in grade selection, polymer ratios, particle engineering, granulation, compression, and validated dissolution performance.

How does Hysingla ER use excipients for abuse deterrence?

Hysingla ER is an abuse-deterrent formulation under the FDA's physical and chemical manipulation category.[2] Its tablet design is intended to make common manipulation methods less effective, including:

• Crushing or grinding.
• Heating.
• Solvent extraction.
• Conversion into an injectable or snortable product.
• Rapid release after mechanical disruption.

The formulation strategy is based on a combination of high tablet strength, polymer-mediated viscosity, and limited drug extraction. In practice, abuse-deterrent performance depends on the interaction between the active pharmaceutical ingredient and the entire matrix. A substitute excipient with the same compendial name may not reproduce the same performance because viscosity, moisture, particle morphology, and compression behavior can differ.

Which excipient characteristics matter most?

The highest-value attributes are:

• Hypromellose viscosity at the selected concentration.
• Polymer hydration rate.
• Ethylcellulose permeability.
• Moisture content.
• Bulk density and flow properties.
• Particle-size distribution.
• Lubricant sensitivity.
• Tablet tensile strength.
• Resistance to crushing and extraction.
• Dissolution after mechanical manipulation.

A supplier selling an excipient into an abuse-deterrent opioid product must support more than a certificate of analysis. Customers typically require lot-to-lot consistency, compendial compliance, extractables and leachables data, change-control discipline, and technical support for dissolution and tamper-resistance testing.

What formulations are protected by Hysingla ER's intellectual property?

Hysingla ER's product protection is directed primarily to the drug product, controlled-release architecture, manufacturing process, and abuse-deterrent performance rather than to broad ownership of individual excipients.

The relevant intellectual-property categories include:

IP category	Commercial relevance
Controlled-release matrix composition	Protects the combination and proportion of release-control materials
Polymer-based abuse deterrence	Covers resistance to crushing, extraction, or rapid release
Tablet manufacturing process	Can restrict process replication even when the excipients are available
Dosage-strength architecture	Supports multiple hydrocodone strengths using a common platform
Method-of-use claims	May cover once-daily treatment of chronic pain
Product-specific patents	May delay or complicate generic approval depending on listing and enforceability

The FDA Orange Book identifies patents and regulatory exclusivities associated with approved drug products, but it does not separately identify "excipient patents." A competitor can often purchase the same compendial materials while still facing risk from formulation, process, method-of-use, or product-by-process claims.[3]

A freedom-to-operate analysis therefore must compare:

• Polymer identity and grade.
• Polymer concentration and ratio.
• Manufacturing sequence.
• Granulation or dry-blending method.
• Compression parameters.
• Dissolution profile.
• Abuse-deterrence test results.
• Labeling and proposed indications.
• Orange Book-listed patents and litigation history.

When does Hysingla ER lose exclusivity?

Hysingla ER's commercial exclusivity is governed by several separate dates:

1. FDA regulatory exclusivity.
2. Orange Book-listed patent expiration dates.
3. Pediatric exclusivity, if applicable.
4. Patent-term adjustments or extensions.
5. Litigation outcomes involving Paragraph IV certifications.
6. Generic approval timing and any first-filer exclusivity.

The original FDA approval date was November 20, 2014.[1] Hysingla ER is not a biologic, so biosimilar rules do not apply. Any competitive entry must proceed through the abbreviated new drug application pathway, generally with an ANDA referencing the listed drug.

Exact launch timing cannot be determined from the FDA approval date alone. A generic applicant must evaluate the current Orange Book listing, patent certifications, exclusivity status, and any applicable settlement or court order.[3]

What is the Orange Book status of Hysingla ER?

The Orange Book is the controlling public source for listed patents, therapeutic-equivalence evaluations, and approved product information.[3] For Hysingla ER, the relevant regulatory questions are:

• Which patents remain listed?
• Which patents cover the formulation rather than only a method of use?
• Has any patent received pediatric exclusivity?
• Are there approved ANDAs?
• Has the FDA assigned a therapeutic-equivalence rating?
• Are any patents subject to Paragraph IV litigation?
• Have any generic applicants entered a settlement agreement?

The Orange Book does not establish that a generic product will be unable to launch. It identifies listed patents and exclusivities that create potential regulatory barriers. A generic applicant may certify that a patent is invalid, unenforceable, or not infringed, which can trigger patent litigation.

Which companies are challenging Hysingla ER?

Public competitive analysis should distinguish among:

• ANDA applicants with Paragraph IV certifications.
• Generic manufacturers with tentative approval.
• Companies developing non-equivalent extended-release hydrocodone products.
• Suppliers selling excipients or processing equipment.
• Developers pursuing alternative abuse-deterrent opioid platforms.

A Paragraph IV challenge does not establish that a generic will launch. Litigation, settlement terms, regulatory deficiencies, manufacturing readiness, and market economics can delay entry.

Because Hysingla ER is a controlled substance and an abuse-deterrent product, generic development is more complex than conventional hydrocodone tablets. The applicant must match release performance and demonstrate that its product meets the applicable abuse-deterrent expectations for the proposed labeling. A formulation that is therapeutically equivalent but easier to crush or extract may face commercial and regulatory disadvantages.

What generic entry risks exist for Hysingla ER?

Generic entry risk is moderate to high over the long term but is constrained by technical and regulatory barriers.

Technical barriers

A generic manufacturer must reproduce:

• Extended-release dissolution across all strengths.
• Dose proportionality.
• Tablet mechanical properties.
• Stability under moisture and temperature stress.
• Consistent hydrocodone content uniformity.
• Manufacturing controls for a high-potency opioid.
• Resistance to common manipulation methods.

Regulatory barriers

The ANDA applicant must address bioequivalence and product quality. The FDA's abuse-deterrent guidance also creates a higher evidence burden for a product seeking comparable abuse-deterrent labeling.[2]

Commercial barriers

Hysingla ER competes with other extended-release opioids, including abuse-deterrent and non-abuse-deterrent products. Payers may prefer lower-cost generic alternatives, but a generic may not receive the same abuse-deterrent labeling unless it satisfies the relevant requirements.

The most likely generic launch scenarios are:

Scenario	Market impact
Single generic with limited strengths	Moderate price pressure; branded product may retain selected contracts
Multiple generic suppliers	Substantial erosion in reimbursement and net sales
Generic without equivalent abuse-deterrent labeling	Segmented competition, with reduced substitution in some channels
Authorized generic or settlement-based launch	Earlier erosion with controlled pricing
No viable generic because of formulation complexity	Continued value for the branded product and excipient platform

What are the best commercial opportunities in Hysingla ER's excipient strategy?

Functional excipient supply

The most immediate opportunity is supplying high-consistency hypromellose, ethylcellulose, povidone, and processing aids to controlled-release developers. Suppliers can differentiate through:

• Narrow viscosity specifications.
• Better flow and compressibility.
• Low moisture variability.
• Strong global regulatory files.
• Technical support for scale-up.
• Stability data in high-drug-load matrices.

Abuse-deterrent formulation platforms

A broader opportunity is a licensable polymer platform for abuse-deterrent oral dosage forms. Potential applications include:

• Extended-release opioids.
• Stimulants with diversion risk.
• Sedatives.
• Central nervous system drugs.
• High-potency analgesics.
• Combination products requiring tamper resistance.

The platform value increases if the technology works across multiple APIs without major changes to dissolution, tablet size, or manufacturing equipment.

Generic development services

Contract development and manufacturing organizations can offer Hysingla-like capabilities, including:

• Formulation screening.
• Drug-excipient compatibility studies.
• Compression development.
• Abuse-deterrence testing.
• Dissolution method development.
• Scale-up and validation.
• Controlled-substance manufacturing.

This market has higher barriers than ordinary modified-release tablets because the developer must coordinate formulation, analytical, clinical, regulatory, and controlled-substance compliance work.

Licensing and acquisition targets

Potential licensing targets include:

• Polymer combinations with demonstrated crush resistance.
• Solvent-resistant matrix systems.
• High-load direct-compression technologies.
• Manufacturing processes that reduce tablet weight.
• Technologies that preserve tamper resistance across multiple strengths.
• Analytical methods that predict abuse-deterrent performance.

Licensing value depends on claim breadth, freedom to operate, regulatory precedent, manufacturing reproducibility, and the ability to apply the platform to multiple APIs.

How does Hysingla ER compare with conventional extended-release hydrocodone?

Attribute	Hysingla ER	Conventional extended-release tablet
Dosing frequency	Once daily	Product dependent
Active ingredient	Hydrocodone bitartrate	Usually hydrocodone-based
Release system	Polymer matrix with hydrophilic and hydrophobic controls	May use matrix, coating, or multiparticulate system
Abuse-deterrent design	Yes, according to FDA labeling	May not have abuse-deterrent labeling
Excipient value	High functional importance	Often lower differentiation
Generic complexity	High	Variable
Commercial differentiation	Tamper resistance and 24-hour dosing	Price, dosage convenience, and supply

Key Takeaways

• Hysingla ER uses hypromellose and ethylcellulose as the core release-control excipient system.
• Lactose, povidone, colloidal silicon dioxide, and magnesium stearate support tablet manufacture and performance.
• The commercial value is in the formulation architecture and processing controls, not in commodity excipient ownership.
• Abuse-deterrent performance depends on polymer grade, ratio, compression, tablet strength, and extraction behavior.
• Hysingla ER is subject to generic-entry analysis through the ANDA and Orange Book framework, not biosimilar regulation.
• Generic development faces higher technical barriers than conventional extended-release hydrocodone development.
• The strongest business opportunities are functional excipient supply, abuse-deterrent platform licensing, formulation development, and controlled-substance manufacturing services.

FAQs

Can Hysingla ER excipients be substituted directly?

No. A different hypromellose or ethylcellulose grade can change hydration, permeability, tablet hardness, dissolution, and extraction behavior. Substitution requires formulation and quality comparability work.

Is Hysingla ER's abuse-deterrent property caused by one excipient?

No. The property results from the combined tablet system, including polymer selection, excipient ratio, drug loading, compression, and manufacturing process.

Can a generic use the same Hysingla ER excipients?

Potentially, but use of the same excipients does not eliminate patent, process, bioequivalence, or abuse-deterrence risks. The applicant must independently satisfy FDA requirements.

Are Hysingla ER excipients subject to controlled-substance regulation?

The excipients generally are not controlled substances. Hydrocodone manufacturing, handling, storage, recordkeeping, and distribution remain subject to DEA and applicable state requirements.

Does Hysingla ER have biosimilar competition?

No. Hysingla ER is a small-molecule oral tablet. Competitive copies would generally use the ANDA pathway rather than the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2014). Hysingla ER prescribing information. FDA/DailyMed. https://dailymed.nlm.nih.gov/dailymed/

2. U.S. Food and Drug Administration. (2015). General principles for evaluating abuse-deterrent properties of opioid drug products: Guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-principles-evaluating-abuse-deterrent-properties-opioid-drug-products

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/